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Background: The profile of cognitive and behavioral variation observed in individuals with fragile X syndrome (FXS),
the most common known cause of inherited intellectual impairment, suggests aberrant functioning of specific brain
systems. Research investigating animal models of FXS, characterized by limited or lack of fragile X mental retardation
protein, (FMRP), has linked brain dysfunction to deficits in the cholinergic and glutamatergic systems. Thus, we sought
to examine in vivo levels of neurometabolites related to cholinergic and glutamatergic functioning in males and
females with FXS.
Methods: The study participants included 18 adolescents and young adults with FXS, and a comparison group of
18 individuals without FXS matched for age, sex and general intellectual functioning. Proton magnetic resonance
spectroscopy (MRS) was used to assess neurometabolite levels in the caudate nucleus, a region known to be
greatly enlarged and involved in abnormal brain circuitry in individuals with FXS. A general linear model
framework was used to compare group differences in metabolite concentration.
Results: We observed a decrease in choline (P = 0.027) and in glutamate + glutamine (P = 0.032) in the caudate
nucleus of individuals with FXS, relative to individuals in the comparison group.
Conclusions: This study provides evidence of metabolite differences in the caudate nucleus, a brain region of
potential importance to our understanding of the neural deficits underlying FXS. These metabolic differences may
be related to aberrant receptor signaling seen in animal models. Furthermore, identification of the specific
neurometabolites involved in FXS dysfunction could provide critical biomarkers for the design and efficacy
tracking of disease-specific pharmacological treatments.
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Fragile X syndrome (FXS), the most common cause of
inherited intellectual disability, affects approximately 1
in 5,000 males and 1 in 10,000 females [1]. FXS results from
a trinucleotide CGG repeat expansion on the long arm of
the X chromosome (locus Xq27.3) [2], hypermethylation of
the fragile X mental retardation 1 (FMR1) gene promoter
region and reduced production of the fragile X mental* Correspondence: areiss1@stanford.edu
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reproduction in any medium, provided the orretardation protein (FMRP). Reduced FMRP expression
has been linked to increased density of immature dendritic
spines and abnormal dendritic morphology in humans with
FXS [3] and mouse models of FXS (Fmr1-knockout (KO)
mouse) [4]. FMRP is implicated in a variety of neurobio-
logical functions, including the mammalian target of rapa-
mycin (mTOR) [5] and the extracellular signal-regulated
kinase 1/2 (ERK1/2) pathways [6].
Reduced FMRP results in a constellation of behavioral
and cognitive impairments, including specific weaknesses
in social cognition, communication and executive function
[7-9], in addition to neurological abnormalities. One oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and bilaterally enlarged caudate nucleus in FXS [10-12].
The caudate, via connections with the frontal lobe, is
involved in impulse control and attention [13], key ex-
ecutive functions known to be deficient in individuals
with FXS [9]. Accordingly, recent functional magnetic
resonance imaging (fMRI) research in individuals with
FXS has found evidence for alterations in the frontostriatal
circuitry underlying executive function skills, including
working memory and attention/inhibition [14].
Other neuroimaging research implicates specific neuro-
transmitter systems involving choline, glutamine and
gamma-aminobutyric acid (GABA) [15,16]. Research ex-
amining metabolic systems in FXS has burgeoned follow-
ing the finding that silencing FMRP in the Fmr1-KO
mouse results in amplified signaling through specific G
protein coupled receptors (GPCRs) – group I metabo-
tropic glutamate receptors (mGluR1 and mGluR5) [17]
and muscarinic acetylcholine receptors (mAChRs) [18].
Potential therapeutic interventions have been suggested
based on genetic and pharmacological manipulations,
which regulate GPCR signaling in Fmr1-KO mice, and
subsequently result in reduction of some maladaptive
behaviors associated with FXS [18,19]. Identification of
affected brain systems in humans with FXS can provide
links between the direct biological consequences of FMRP
silencing and the neurobiological/behavioral/cognitive
phenotypes of FXS, as well as provide endpoints for
monitoring pharmacological intervention.
To date, examination of specific brain systems in humans
with FXS is very limited. One in vivo investigation of
neurometabolite levels in males with FXS reported re-
duced choline/creatine ratios in bilateral dorsolateral pre-
frontal cortex [15], an integral part of the corticostriatal
executive functioning network in which aberrant function-
ing has been demonstrated in humans with FXS [14].
The present study sought to examine neurometabolite
levels in a broader sample of individuals with FXS, in-
cluding both females and males, to address the hypoth-
esis that similar neurometabolic profiles are present in
both sexes. Females, like males with fragile X syndrome,
have reduced FMRP, and disadvantageous cognitive and
behavioral symptoms, albeit to a lesser degree than their
male counterparts [20]. Furthermore, structural brain
abnormalities, including enlarged caudate nucleus, are
present in both males and females with FXS, although
some reports indicate less severe abnormalities for
females [10,21-23]. An innovative component of the
current study is that individuals with FXS were com-
pared to individuals without FXS matched for age, sex
and general intellectual functioning. Thus significant
differences observed in neurometabolite profiles would
be primarily linked to FXS and not cognitive function-
ing in general.We examined the caudate nucleus because previous evi-
dence has indicated this region’s importance to our under-
standing of the neurobiological basis of FXS [10-12,14,24].
Metabolic concentrations for the major proton metab-
olites were estimated with in vivo single-voxel proton
magnetic resonance spectroscopy (MRS) and included
N-acetylaspartate (NAA), creatine, choline, myo-inositol,
glutamate, and glutamine + glutamate (Glx). We hypothe-
sized that individuals with FXS, including females, would
display lower levels of choline and glutamate-related
metabolites relative to the comparison group.
Methods
The participants included 27 adolescents and young adults
with FXS (confirmed via evidence of full FMR1 mutation
on DNA testing utilizing standard Southern blot tech-
niques; mean age = 20.79 years, SD = 3.38, 18 females),
and a comparison group of 24 individuals without FXS
(confirmed via genetic screening [25]; mean age = 19.64 years,
SD = 2.82, 13 females). Participants in the comparison
group were diagnosed with idiopathic developmental
delay, intellectual disability or learning disability, and were
matched to the FXS group for age, sex and general intel-
lectual level (Ps >0.10). Potential participants in the com-
parison group were excluded for any other known genetic
condition, premature birth, low birth weight, or a history
of severe psychiatric, neurological or medical disorder.
Participants were free from magnetic resonance imaging
(MRI) contraindications. Participants were recruited across
the USA and Canada through advertisements, referrals,
word of mouth and from our database. Participants
and/or their parents gave written informed consent and
assent to participate in the study. All protocols were ap-
proved by the Institutional Review Board at Stanford
University, CA, USA.
Participant medications were grouped into three classes:
1) stimulants; 2) selective serotonin reuptake inhibitors
(SSRIs); and 3) atypical antipsychotics, anticonvulsants
and other drugs affecting neurological functioning. The
association of medication class with metabolite concen-
tration was assessed via multiple regression, separately
in each participant group. One participant in the FXS
group was taking the acetylcholinesterase inhibitor donep-
ezil. Given this drug’s intended effect on the cholinergic
system we considered this participant a potential outlier
for all subsequent analyses.
General intellectual function was assessed via the
Wechsler Abbreviated Scale of Intelligence (age 17 years
or older) [26] or the Wechsler Intelligence Scale for
Children (age younger than 17 years) [27]. Executive
functioning was assessed via the Contingency Naming
Test (CNT), a measure of processing speed and inhibition
[28]. Parent ratings included the Aberrant Behavior
Checklist [29] which measures problem behaviors and
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tion subscale which measures attention problems [30,31].
Participants were scanned on a 3 Tesla MRI Scanner
(GE Signa, Milwaukee, WI, USA) at the Lucas Center
for Neuroimaging, Stanford University, using one of two
custom single-channel quadrature head coils (one head
coil was decommissioned midway through the study).
A T2-weighted gradient echo spiral pulse sequence
(TE1 = 17 ms, TE2 = 85.0 ms, TR = 4000 ms, FOV= 24 cm,
slice thickness = 5 mm, gap = 0 mm, slices = 19, frequency
x phase = 256 × 192) was used to produce an image on
which a 1.5 cm isotropic voxel was prescribed, encom-
passing as much of the right caudate head as possible
(Figure 1). Given the voxel’s cubic shape and its size
(larger than the caudate head) the voxel included por-
tions of the adjacent lateral ventricle, the surrounding
periventricular and frontal white matter, and the anter-
ior aspect of the putamen. Due to scanning duration
limitations we were only able to examine one region of
interest and we chose the right hemisphere given itsFigure 1 Example voxel placement. MRS voxel (black square) displayed on
the comparison group). (A) Axial, (B) coronal and (C) sagittal. We placed 1.5 c
were placed to maximize caudate head tissue. Note: original voxel was positio
shown here for enhanced resolution in sagittal and coronal planes. A, anterio
R, right; S, superior.strong implication in FXS-deficient executive function-
ing networks [14].
Single-voxel MRS of this region was acquired via constant-
time point-resolved spectroscopy (CT-PRESS; average
TE = 139 ms, n1 = 129, Δt½ = 0.8 ms) [32]. The resulting
spectra were analyzed with MATLAB (Natick, MA, USA)
as described previously [33]. Metabolite signals, deter-
mined by peak integration (with an interval of ±6 Hz), in-
cluded the major proton metabolites, NAA (2.01 ppm),
creatine (3.03 and 3.93 ppm), choline (3.24 ppm), myo-
inositol (3.58 ppm), glutamate (2.36 ppm) and Glx
(3.78 ppm) (Figure 2). An acquisition was acquired with-
out water suppression to measure tissue water content
(including cerebrospinal fluid (CSF)), which was then used
to normalize concentrations of each metabolite thus
accounting for tissue fraction in the voxel [33,34].
Spectra were included only if the signal-to-noise ratio
(SNR) of the NAA peak was equal to or greater than 15
and the spectral line width was less than 20 Hz. Nine
spectra from participants in the FXS group and sevenhigh resolution T1-weighted image for one example participant (from
m isotropic voxels over the head of the right caudate nucleus. Voxels
ned on T2-weighted image, but high resolution T1-weighted image is
r; I, inferior; L, left; MRS, magnetic resonance spectroscopy; P, posterior;
Figure 2 Example spectra. Example spectra for one individual from the comparison group (left) and one individual from the FXS group (right).
Signal is in arbitrary units. Cho, choline; Glu, glutamate; Glx, glutamine + glutamate; mI, myo-inositol; NAA, N-acetylaspartate; tCr, creatine.
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eliminated, resulting in a final sample size of 18 partici-
pants with FXS (14 females) and 18 participants in the
comparison group (ten females). These smaller groups




Verbal IQ FXS 18
Comparison 18
Performance IQ FXS 18
Comparison 18
Full Scale IQ FXS 18
Comparison 18
Contingency Naming Test (CNT) FXS 16
Comparison 16
Aberrant Behavior Checklist FXS 15
Comparison 17











Standard scores are reported for Verbal, Performance and Full Scale IQ; higher score
(out of 27) divided by the time to completion; higher scores indicate better performan
indicate greater prevalence of aberrant behavior. Achenbach attention refers to the Ad
test (range = 1 to 100, mean = 50); higher scores indicate greater attention problems. C
Other, atypical antipsychotics, anticonvulsants and other drugs affecting neurological fand all subsequent reporting includes only this final
sample (Table 1).
The coordinate location of the MRS voxel was used to
prescribe a corresponding 1.5 cm isotropic voxel on
each participant’s T2-weighted anatomical image. BrainMean Minimum Maximum SD
20.54 15.39 25.85 3.57
19.80 16.59 25.85 2.61
80.22 46 119 21.08
72.56 46 100 18.77
72.78 48 118 18.46
76.89 55 121 20.36
74.56 44 119 20.61
72.72 48 111 19.68
17.73 6.61 47.65 10.32
17.02 4.29 36.00 9.93
19.33 0 90 24.85
19.65 0 74 19.68
59.65 50 83 9.36










s indicate better performance. The CNT score is the number of items correct
ce. Raw scores are reported for the Aberrant Behavior Checklist; higher scores
ult or Child Behavior Checklist attention subscale, T scores are reported for this
NT Contingency Naming Test, FXS fragile X syndrome, IQ intelligence quotient,
unctioning; SSRI selective serotonin reuptake inhibitor.
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Centre for Functional MRI of the Brain (Oxford, UK;
FSL, http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/) were used to seg-
ment each T2-weighted image, and calculate the percent-
age of each tissue type (grey matter, white matter, CSF)
within each MRS voxel.
Our primary analysis compares metabolite ratios rela-
tive to creatine (3.03 ppm), but we also report absolute
values as a secondary analysis. A general linear model
framework was employed to evaluate group differences
in metabolite concentrations and performance on cognitive/
behavioral assessments. Our primary goal was to compare
group differences in choline and glutamate-related metabo-
lites; comparisons of NAA and myo-inositol are included as
exploratory analyses. Thus, multiple comparison correction
was not warranted. Although the number of participants
scanned with each head coil type did not differ between
groups (χ2 = 0.468, P >0.10), head coil type was related to
within group metabolite concentration and was therefore
added as a covariate in analyses of metabolite concentration.
The MRS voxel contained a greater proportion of grey
matter (P = 0.015) and a correspondingly smaller propor-
tion of CSF (P = 0.035) for individuals with FXS relative
to individuals in the comparison group; white matter
proportions did not differ (P >0.10, Table 2). SNR and
line width did not differ between groups (Ps >0.10). The
model assessing group differences in metabolite concen-
tration ratios included group (FXS versus comparison)
as the independent variable, metabolite concentration
ratio as the dependent variable, and head coil type andTable 2 Metabolite concentrations
Metabolite concentrations Group Mean SD
NAA/creatine FXS 1.23 0.15
Comparison 1.38 0.24
Glutamate/creatine FXS 0.19 0.13
Comparison 0.20 0.11
Choline/creatinea FXS 0.78 0.11
Comparison 0.87 0.14
myo-inositol/creatine FXS 0.14 0.05
Comparison 0.13 0.06
Glx/creatinea FXS 0.20 0.10
Comparison 0.26 0.10
Voxel composition (% total volume)
Grey mattera FXS 0.35 0.03
Comparison 0.33 0.02
White matter FXS 0.34 0.04
Comparison 0.33 0.02
Cerebrospinal fluid (CSF)a FXS 0.31 0.06
Comparison 0.34 0.03
aSignificant group difference. CSF cerebrospinal fluid, FXS fragile X syndrome,
Glx glutamine + glutamate, NAA N-acetylaspartate.grey matter percentage as covariates. Due to the high
variability in absolute metabolite values we used the non-
parametric Mann–Whitney U test, and thus were unable
to account for head coil type and grey matter percentage
as covariates at the group level for these absolute values,
but metabolite concentrations were normalized for voxel
tissue fractions at the individual level. We assessed within
group relationships between metabolite concentration
ratios and cognitive/behavioral assessment scores with
two-tailed Pearson’s correlations.
Results
All results are presented for the 18 participants in each
group with useable spectra. Age, cognitive test scores
and parent reports of behavior did not differ between
groups (all Ps >0.10, Table 1). Of this final set of par-
ticipants, eight individuals in each group were taking
medications in one or more of the classes listed: 1)
stimulants; 2) SSRIs; and 3) atypical antipsychotics, anti-
convulsants and other drugs affecting neurological func-
tioning. The number and percentage of individuals in
each group taking each class of medication is presented in
Table 1. Within the FXS group, three individuals were
taking SSRIs only, five individuals were taking medications
in class 3 only, two individuals were taking both stimulants
and SSRIs, and three individuals were taking both SSRIs
and medications in class 3. Within the comparison group,
five individuals were taking stimulants only, one individual
was taking an SSRI only, one individual was taking a medi-
cation in class 3 only, and three individuals were taking
both stimulants and SSRIs.
We observed reduced choline/creatine ratios (P = 0.027)
and Glx/creatine ratios (P = 0.032) in the FXS group rela-
tive to the comparison group (Table 2, Figure 3). There
was a trend for reduced NAA/creatine in the FXS group
(P = 0.082); glutamate/creatine and myo-inositol/creatine
concentrations did not differ (Ps >0.10). The pattern of
results and significance did not change with the individ-
ual taking donepezil excluded: the FXS group displayed
reduced choline/creatine (P = 0.015) and Glx/creatine
(P = 0.025); NAA/creatine, glutamate/creatine and myo-
inositol/creatine levels did not differ (Ps >0.10). When
comparing absolute values we observed reduced choline
(P = 0.010), Glx (P = 0.031) and NAA (P = 0.012) in the
FXS group relative to the comparison group. Glutamate,
myo-inositol and creatine concentrations did not differ
(Ps >0.10).
Choline/creatine and Glx/creatine ratios were also com-
pared between female only subgroups (14 females in FXS
group, ten females in comparison group), which did not
differ in age or general intellectual functioning (Ps >0.10).
For females only, the FXS group displayed signifi-
cantly lower choline/creatine (P= 0.027) and Glx/creatine
(P= 0.043) levels relative to the comparison group. Statistical
Figure 3 Metabolite concentration by group. Metabolite concentrations are in arbitrary units, relative to creatine. * indicates significant group
difference. FXS group N = 18; comparison group N = 18. Group means are indicated by horizontal line. FXS, fragile X syndrome; NAA, N-acetylaspartate.
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to sample size (four males in FXS group, eight males in
comparison group), although effect sizes for between
group differences in choline/creatine and Glx/creatine
levels were similar to those for females (choline/creatine
Glass’s Δ female = 0.569, male = 0.513; Glx/creatine Glass’s
Δ female = 0.546, male = 0.604).
Within group analysis of medication effects on each
metabolite ratio indicated that metabolite concentration
was not significantly related to medication status in either
group (all Ps >0.10). Group comparisons of metabolite
concentration were repeated including only medication-
free individuals (ten individuals in each group). Choline/
creatine and Glx/creatine levels were lower for the FXS
group, but the differences did not reach significance
(Ps >0.10).
As an exploratory analysis we examined within group
correlations between metabolites for which we found a
significant group difference – choline/creatine and Glx/
creatine – age, and cognitive/behavioral scores. There
were no significant correlations within either group (all
Ps >0.10); results did not change when excluding the
participant taking donepezil (Ps >0.10).
Discussion
The present study employed single-voxel MRS to exam-
ine in vivo neurometabolite concentrations in humans
with FXS and provides direct evidence of altered metab-
olite concentration in the caudate nucleus. We demon-
strate significantly reduced levels of choline/creatine and
Glx/creatine in a group of males and females with FXS,
relative to a group of individuals without FXS who were
matched for age, sex and general intellectual function-
ing. These results are in line with the only previously
published human FXS MRS study [15] and they corrobor-
ate previous reports of altered neurometabolic functioning
in animal models of FXS [16]. Aberrant neurometabolitelevels may underlie some of the clinical symptoms seen in
FXS and they may be related to aberrant receptor signal-
ing seen in animal models [17,18].
FXS has previously been associated with greatly en-
larged caudate size [10-12] and aberrant frontostriatal
executive functioning networks [14,24]. We provide evi-
dence for altered metabolite concentrations, further elu-
cidating atypical caudate neurobiology in FXS. Given the
caudate’s role in learning, memory and executive func-
tions [13], aberrant metabolite levels in this region may
mediate some of the behavioral and cognitive deficits
associated with FXS. Although the precise effects of FMRP
on neurometabolism are not fully understood, recent find-
ings indicate that lack of FMRP results in aberrant func-
tioning of specific GPCRs, mAChRs and mGluRs [17,18],
which are highly expressed in striatal circuits [35]. There-
fore, the altered neurometabolite levels reported here may
be related to hypersensitive mAChR and mGluR signaling.
Additionally, FMRP plays a role in regulating calcium-
dependent potassium (BK) channels, which are highly
expressed in striatal circuits and may also contribute to
altered metabolite levels [36]. The direct causal pathway
between hypersensitive receptor functioning, BK channel
dysregulation and decreased metabolite levels revealed by
MRS has yet to be determined, but our results provide an
important, although indirect, link.
Glutamate, glutamine and GABA contribute to the
Glx peak at 3.78 ppm, although the contribution of GABA
is extremely small [37]. Glutamate and glutamine levels
are indirectly related to glutamatergic signaling, which is
critical for synaptic plasticity and learning [38]; thus,
decreased Glx may be a biomarker for learning deficits
associated with FXS. A pilot study examining premutation
carriers of the FMR1 gene did not find glutamatergic ab-
normalities in this condition [39], which is associated with
between 55 to 200 CGG repeats and generally normal,
though potentially variable overall FMRP production [40].
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reported for individuals with autism spectrum disorders
(ASD) [41], a set of behaviorally defined disorders in
which cognitive and behavioral symptoms overlap with
those observed in FXS [42]. As with FXS, animal models
of ASD have revealed functional abnormalities in both
excitatory (glutamate) and inhibitory (GABA) systems
[43-45]. These findings suggest some degree of common
neurobiological alteration despite differential origin for
cognitive and behavioral symptoms in FXS (reduced
FMRP) and idiopathic ASD (variable unknown causes).
MRS examinations of ASD have reported decreased
levels of NAA [46,47], which has not been previously
shown in FXS, although we did report a trend for lower
NAA/creatine ratios and lower absolute NAA in FXS.
Future studies comparing ASD to FXS directly may be
needed to understand common and divergent neurobio-
logical underpinnings.
The MRS visible choline peak at 3.22 ppm includes
phosphocholine and glycerophosphocholine, phospholipids
involved in membrane synthesis and integrity, which are
markers of cellular density [48]. Decreased choline within
the FXS group may be indicative of decreased overall cellu-
lar density in the caudate. Free choline, the precursor for
acetylcholine, represents a relatively small portion of the
MRS visible choline peak, yet this peak correlates with
in vivo acetylcholine measured in rat brain [49]. This
animal research suggests reduced choline may indicate
altered acetylcholine levels in humans, but more evidence
is needed to determine the reliability of MRS signal as a
marker of acetylcholine level. Such a non-invasive marker
would be extremely useful for the study of FXS given the
evidence for altered acetylcholine receptor signaling in
Fmr1-KO mice [18].
Our primary results suggest that choline and Glx differ-
ences are present in both males and females with FXS.
Analysis for females only confirms that females with FXS
have significantly reduced choline and Glx which, in
context with previous research demonstrating altered
metabolite levels in males [15], indicates that these
neurometabolic systems may be viable candidates for
pharmacological treatment endpoints in both sexes. We
did not have a large enough sample of male participants
to draw conclusions regarding males, but similar effect
sizes for male and female participants indicate that simi-
lar altered metabolite concentration may exist in both
sexes. Future studies with larger sample sizes in each
sex are essential for expanding knowledge in this area.
We explored the relationship between neurometabolite
concentration and cognitive/behavioral functioning within
each group, but found no significant correlations. The
measures of cognitive/behavioral functioning we utilized
may not have been sensitive enough to detect such rela-
tionships and we did not include specific measures oflearning or memory, which may be related to choline [50]
and glutamine [38] metabolism. Furthermore, sex differ-
ences or medication usage may have obscured the rela-
tionship between cognitive/behavioral functioning and
metabolite concentration. Larger sample sizes, wider age
ranges and longitudinal data points are required to clearly
elucidate such complex brain/behavior relationships.
The nature of our study population dictated inclusion
of participants taking medication and, although there was
no within group relationship between metabolite concen-
tration and medication usage, we cannot rule out the
possibility that medication has some effect on metabolite
concentration. Our post hoc analysis including only
medication-free individuals showed a trend for lower
choline/creatine and Glx/creatine for the FXS group,
but differences did not reach significance. Including
only medication-free individuals biased our sample to-
ward higher functioning individuals in each group and
reduced the statistical power. Larger-scale investigations
are required to adequately address the relationships among
metabolite concentration, medication usage and pheno-
types associated with FXS.
We present metabolite data referenced to creatine, a
metabolite widely used as a reference in human MRS,
because its concentration remains stable regardless of
changes in energy metabolism or disease progression [51],
although research suggests creatine levels may be altered
in the Fmr1-KO mouse [16]. Therefore, we conducted a
secondary analysis using absolute water referenced values
for each metabolite and noted significant group differ-
ences in choline and Glx, as well as in NAA. We interpret
the difference in NAA with caution, since we were not
able to account for group level covariates in the analysis
of absolute concentration and we noted only a trend for
lower values in the FXS group on the NAA/creatine
ratio. Importantly, we did not find a significant group
difference in creatine, supporting the use of that metabol-
ite as a reference in our analysis. We were unable to quan-
tify GABA or glutamine concentrations individually, or to
examine more than one region of interest, given our
limited time frame for MRI data acquisition. Future in-
vestigations employing higher magnet strength, spectral
editing and multi-voxel imaging may further elucidate
the neurometabolic alterations in FXS.
Conclusions
We have demonstrated a significant decrease in choline
and a combined measure of glutamate and glutamine in
the caudate of individuals with FXS, as compared to indi-
viduals matched for age, sex and intellectual functioning.
These findings corroborate previous reports that FXS is
associated with deficits in choline and glutamate-related
neurometabolites. Further research is required to deter-
mine the exact causal pathway between limited FMRP and
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tween in vivo metabolite concentrations and hypersensi-
tive cholinergic and glutamatergic receptor functioning
reported in animal models. Identification of the specific
neurometabolic changes involved in FXS dysfunction could
produce critical biomarkers for utilization in disease-
specific pharmacological treatments. Targeted pharmaco-
logical treatments aimed at correcting the neurometabolic
system deficits associated with FXS would represent an
immense improvement over current therapies used to
ameliorate behaviors associated with the disorder. Our
results and animal research [16] suggest multiple neuro-
transmitter system involvement; thus, more than one
targeted treatment may be required to adequately ad-
dress all the behavioral and cognitive issues associated
with FXS. Neurobiological imaging modalities such as
MRS may help elucidate mechanisms and neural cir-
cuits by which absent or reduced FMRP relates to the
behavioral and cognitive deficits associated with FXS.
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